These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38887011)

  • 1. Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
    Guirguis E; Dougherty J; Thornby K; Grace Y; Mack K
    Ann Pharmacother; 2024 Jun; ():10600280241259528. PubMed ID: 38887011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
    N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
    Fishman J; Kim Y; Parisé H; Bercaw E; Smith Z
    J Med Econ; 2024; 27(1):1108-1118. PubMed ID: 39155764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis.
    Raja A; Subhash Sagar R; Saeed S; Zia Ul Haq A; Khan O; Dileep Bhimani P; Raja S; Deepak F; Ahmed M; Ashir Shafique M; Saqlain Mustafa M; Sohaib Asghar M; Sharma V
    Ann Med Surg (Lond); 2024 Jul; 86(7):4130-4138. PubMed ID: 38989228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dutta D; Kamrul-Hasan ABM; Mondal E; Nagendra L; Joshi A; Bhattacharya S
    Endocr Pract; 2024 Jul; 30(7):631-638. PubMed ID: 38697306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resmetirom: First Approval.
    Keam SJ
    Drugs; 2024 Jun; 84(6):729-735. PubMed ID: 38771485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
    Alshehade SA
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102377. PubMed ID: 38772519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
    Harrison SA; Ratziu V; Anstee QM; Noureddin M; Sanyal AJ; Schattenberg JM; Bedossa P; Bashir MR; Schneider D; Taub R; Bansal M; Kowdley KV; Younossi ZM; Loomba R
    Aliment Pharmacol Ther; 2024 Jan; 59(1):51-63. PubMed ID: 37786277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Karim G; Bansal MB
    touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
    Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
    Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
    Younossi ZM; Stepanova M; Taub RA; Barbone JM; Harrison SA
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1354-1361.e7. PubMed ID: 34329774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
    Noureddin M; Charlton MR; Harrison SA; Bansal MB; Alkhouri N; Loomba R; Sanyal AJ; Rinella ME
    Clin Gastroenterol Hepatol; 2024 Jul; ():. PubMed ID: 39038768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.
    Kuchay MS; Isaacs S; Misra A
    Diabetes Metab Syndr; 2024 May; 18(5):103034. PubMed ID: 38714040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.
    Sun K; Zhu NL; Huang SL; Qu H; Gu YP; Qin L; Liu J; Leng Y
    Acta Pharmacol Sin; 2024 Oct; 45(10):2134-2148. PubMed ID: 38789494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
    Harrison SA; Taub R; Neff GW; Lucas KJ; Labriola D; Moussa SE; Alkhouri N; Bashir MR
    Nat Med; 2023 Nov; 29(11):2919-2928. PubMed ID: 37845512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
    Puengel T; Tacke F
    Expert Opin Pharmacother; 2024 Jun; 25(9):1249-1263. PubMed ID: 38954663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals.
    Au K; Zheng MH; Lee WJ; Ghanem OM; Mahawar K; Shabbir A; le Roux CW; Targher G; Byrne CD; Yilmaz Y; Valenti L; Sebastiani G; Treeprasertsuk S; Hui HX; Sakran N; Neto MG; Kermansaravi M; Kow L; Seki Y; Tham KW; Dang J; Cohen RV; Stier C; AlSabah S; Oviedo RJ; Chiappetta S; Parmar C; Yang W;
    Curr Obes Rep; 2024 Aug; ():. PubMed ID: 39110384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.